162 related articles for article (PubMed ID: 8864181)
41. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
Swift L; McHowat J; Sarvazyan N
Cancer Res; 2003 Sep; 63(18):5992-8. PubMed ID: 14522926
[TBL] [Abstract][Full Text] [Related]
42. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity.
Seifert CF; Nesser ME; Thompson DF
Ann Pharmacother; 1994 Sep; 28(9):1063-72. PubMed ID: 7803884
[TBL] [Abstract][Full Text] [Related]
43. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.
Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1993; 32(6):445-9. PubMed ID: 8258192
[TBL] [Abstract][Full Text] [Related]
44. [Cardiotoxicity study of ME2303 with the interval intravenous injections to rats].
Aoyama M; Kato S; Kodama I; Toyama J; Watanabe T; Kawaoto H; Asaoka H; Kurebe M
Jpn J Antibiot; 1990 Jul; 43(7):1230-7. PubMed ID: 2232153
[TBL] [Abstract][Full Text] [Related]
45. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
Kik K; Szmigiero L
Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
[TBL] [Abstract][Full Text] [Related]
46. Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection.
Zeidán Q; Strauss M; Porras N; Anselmi G
J Submicrosc Cytol Pathol; 2002 Jul; 34(3):315-21. PubMed ID: 12408365
[TBL] [Abstract][Full Text] [Related]
47. Effects of ICRF 159 on adriamycin-induced cardiomyopathy in rats.
Decorti G; Bartoli Klugmann F; Mallardi F; Klugmann S; Benussi B; Grill V; Baldini L
Cancer Lett; 1983 May; 19(1):77-83. PubMed ID: 6406045
[TBL] [Abstract][Full Text] [Related]
48. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results.
Schiavetti A; Castello MA; Versacci P; Varrasso G; Padula A; Ventriglia F; Werner B; Colloridi V
Pediatr Hematol Oncol; 1997; 14(3):213-22. PubMed ID: 9185206
[TBL] [Abstract][Full Text] [Related]
49. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
50. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
51. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
52. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
53. [Prevention against and treatment of doxorubicin-induced acute cardiotoxicity by dexrazoxane and schisandrin B].
Hu KY; Yang Y; He LH; Wang DW; Jia ZR; Li SR; Tian W; Mao J; Li XJ; Zhang W
Yao Xue Xue Bao; 2014 Jul; 49(7):1007-12. PubMed ID: 25233631
[TBL] [Abstract][Full Text] [Related]
54. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
[TBL] [Abstract][Full Text] [Related]
55. Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria.
Sayed-Ahmed MM; Shouman SA; Rezk BM; Khalifa MH; Osman AM; El-Merzabani MM
Pharmacol Res; 2000 Feb; 41(2):143-50. PubMed ID: 10623482
[TBL] [Abstract][Full Text] [Related]
56. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
Jahnukainen K; Jahnukainen T; Salmi TT; Svechnikov K; Eksborg S; Söder O
Cancer Res; 2001 Sep; 61(17):6423-7. PubMed ID: 11522636
[TBL] [Abstract][Full Text] [Related]
57. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.
Imondi AR
Semin Oncol; 1998 Aug; 25(4 Suppl 10):22-30. PubMed ID: 9768820
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Herman EH; Zhang J; Ferrans VJ
Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
[TBL] [Abstract][Full Text] [Related]
59. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
Langer SW; Sehested M; Jensen PB
Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
[TBL] [Abstract][Full Text] [Related]
60. Peculiarities of adriamycin cardiotoxicity in spontaneously hypertensive rats (SHR).
Herrmann HJ; Massow S; Moritz V; Norden C; Kühne C
Biomed Biochim Acta; 1987; 46(8-9):S593-6. PubMed ID: 3435516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
